Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial

Table 2 Distribution of procedure-related findings at endoscopic retrograde cholangiopancreatography in the 76 participating patients n (%)

Finding/procedure1	Losartan group	Placebo group
Total	38 (100)	38 (100)
Cannulation of the common bile duct
Cannulation difficulty2
Easy or medium	27 (71)	27 (71)
Difficult or failed	10 (26)	9 (24)
Pancreatography
Number of pancreatic duct injections2
None	21 (55)	24 (63)
1-3	15 (39)	11 (29)
≥ 4	1 (3)	2 (5)
Extent of pancreatography2
None	21 (55)	24 (63)
Main duct	12 (31)	11 (29)
First branch, second branch, and acinarisation	4 (11)	2 (5)
Procedure-related findings in bile ducts2
Normal	5 (13)	3 (8)
Gallstone	13 (34)	14 (37)
Suspected cancer	6 (16)	8 (21)
Dilatation, benign or undetermined stricture, or anomaly	14 (37)	10 (26)
Procedure-related findings in pancreas2
Not contrast-fille	21 (55)	24 (63)
Normal	13 (34)	10 (26)
Suspected cancer	0 (0)	1 (3)
Dilatation	3 (8)	1 (3)
Endoscopic procedure
Biliary sphincterotomy
No	11 (29)	14 (37)
Yes	27 (71)	24 (63)
Biliary stenting
No	24 (63)	23 (61)
Yes	14 (37)	15 (39)
ERCP time, min2
< 30	13 (34)	10 (26)
≥ 30	22 (58)	26 (68)
Time between intake of losartan or placebo capsule and ERCP, min
< 60	9 (24)	7 (18)
≥ 60	29 (76)	31 (82)

¹The endoscopist assessed degree of technical difficulty;

²The total number of participants was 38 patients in each variable, and a sum < 38 indicate missing values between n = 2-5. ECRP: Endoscopic retrograde cholangiopancreatography.